skyla



Р

Preanesthetic Panel	Chem C
	PN: 900-100
For Veterinary In Vitro Diagnostic Use Only	Rev : H

1. Intended Use

The skyla Preanesthetic Panel used with skyla Analyzer, is intended to be used for the quantitative determination of Albumin (ALB), Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Blood Urea Nitrogen, (BUN), Creatinine (CREA), Glucose (GLU), Total Protein (TP) in animal whole blood, plasma, or serum. The calculated values of Globulin (GLOB), Albumin/Globulin Ratio (A/G Ratio), Blood Urea Nitrogen/Creatinine Ratio (B/C Ratio) and UREA can then be obtained.

2. Principles

The skyla Preanesthetic Panel contains a total of 7 types of dried reagents located in the respective detection wells of the reagent disc. The user only needs to inject the blood specimens into the sample port of the disc, and then places the disc into the analyzer. The test will be done automatically within 15 minutes. Three additional calculated values are also obtained after the test. For the detail description of disc, please refer to "skyla Analyzer Operator's Manual".

Clinical Significance:

Albumin (ALB): ALB is one of the indicators for kidney function, liver function and dehydration.

Alkaline phosphatase (ALP): ALP is one of the indicators for liver and biliary related diseases.

Alanine Aminotransferase (ALT): ALT is used to detect pet viral hepatitis, cirrhosis, and the degree of liver injury and related diseases.

Blood Urea Nitrogen (BUN): BUN is one of the important markers for diagnosis and prognosis tracking of kidney diseases

Creatinine (CREA): CREA is a marker to examine renal functions.

Glucose (GLU): GLU can be used for the diagnosis of diabetes and diseases related to the carbohydrate metabolism.

Total Protein (TP): TP is an indicator for function of liver synthesis and the degree of protein-losing caused by kidney diseases.

Globulin (GLOB): GLOB is calculated from TP and ALB and it is used to assess liver function.

Albumin/Globulin Ratio (A/G Ratio): The A/G Ratio is the ALB and GLOB ratio. It is used to assess liver function.

Blood Urea Nitrogen/ Creatinine Ratio (B/C Ratio): The B/C Ratio may indicate the degree of kidney injury and azotemia.

UREA : UREA is synthesized in the liver and secreted by the kidneys. Urea is the end product of protein nitrogen metabolism and is the primary vehicle for removing toxic ammonia from the body. The analysis of urea is an important clinical test for renal disease and dysfunction.

Method:

ALB

ALB is determined through the endpoint chemical reaction method. When ALB binding to Bromocresol Green (BCG), it forms a yellow-green complex. The absorbance at a wavelength of 600 nm can be measured. The amount of ALB in the sample is proportional to the bound ALB.

ALP

ALP activity is enzymatically determined. *p*-Nitrophenyl Phosphate that is hydrolyzed by ALP into a yellow colored product *p*-Nitrophenol which has an absorbance at a wavelength of 405 nm. The rate of the reaction is directly proportional to the enzyme activity.

<u>ALT</u>

ALT activity is enzymatically determined. ALT catalyses the alanine with α -Ketoglutarate, and converts them into Glutamate and Pyruvate. In the presence of NADH, Lactate Dehydrogenase converts Pyruvate into Lactate. In the course of the reaction NADH is oxidized to NAD. The decrease of NADH absorbance is measured at a wavelength of 340 nm and is proportional to ALT activity.

<u>BUN</u>

BUN is enzymatically determined. Urea undergoes an Urease catalyzed hydrolysis, thus producing Ammonia and Carbon Dioxide. In a Glutamate Dehydrogenase (GLDH) catalyzed reaction, Ammonia reacts with 2-Oxoglutarate yielding L-Glutamate. In the process of this reaction, β -Nicotinamide Adenine Dinucleotide (NADH) is oxidized to β -Nicotinamide Adenine Dinucleotide (NADH) is oxidized to β -Nicotinamide Adenine at a wavelength of 340 nm is measured and proportional to the BUN concentration.

CREA

CREA is determined through the endpoint enzymatic reaction approach. Creatinine Amidohydrolase hydrolyzes CREA to Creatine. Then Creatine is converted into Sarcosine through catalysis of

Creatine Amidinohydrolase. Furthermore, Sarcosine Oxidase oxidizes Sarcosine, yielding Glycine, Formalehyde and Peroxide (H_2O_2) in the process. The enzyme Peroxidase processes Hydrogen Peroxide, 2,4,6-3 Hydroxy-Benzoic Acid (TBHBA) and 4-Aminoantipyrine (4-AAP), forming a Quinoneimine dye as a product. The dye formation is measured at a wavelength of 546 nm and is proportional to the amount of CREA in the sample.

<u>GLU</u>

GLU is determined through the endpoint enzymatic reaction approach. The Sucrose is catalyzed by Hexokinase to D-Glucose-6-Phosphate (G-6-P). In the presence of NAD, G-6-PD converts G-6-P into 6- Phosphogluconate and NADH. The absorbance at a wavelength of 340 nm can be measured in the presence of NADH. The absorbance is proportional to the GLU concentration.

TP

TP is determined by the Biuret method. The peptide bonds of the protein react with copper ions in an alkaline environment and form a purple compound. The color development is proportional to the original TP concentration and is measured at a wavelength of 546 nm.

Reaction pathway:

<u>ALB</u> Albumin + BCG \longrightarrow Albumin-BCG Complex

ALP

 $p-Nitrophenyl Phosphate \longrightarrow p-Nitrophenol + Phosphate$

<u>ALT</u>

 $Pyruvate + NADH + H^{+} \xrightarrow{LDH} L-Lactate + NAD^{+} + H_{2}O$

<u>BUN</u>

 $Urease \\ Urea + H_2O \xrightarrow{} 2NH_3 + CO_2$

 $\label{eq:hardenergy} \begin{array}{c} \text{GLDH} \\ \text{NH}_3 + 2\text{-Oxoglutarate} + \text{NADH} & \longrightarrow & \text{L-Glutamate} + \text{H}_2\text{O} + \text{NAD}^+ \end{array}$

<u>CREA</u>

 Total protein + Cu^{2+} — — — — — — Cu-Protein Complex

3. Reagents

Included:

Each panel contains dried reagent beads, dried internal QC beads and the diluent.

Reagent Comp	osition:
--------------	----------

Composition	Quantity/Panel
4-APP	0.02 mg
4-Nitrophenyl Phosphate Disodium Salt	0.1 mg
Bromocresol Green Sodium Salt	5.4 µg
Copper Sulphate	0.1 mg
Creatinase	2.8 U
Creatininase	5.6 U
G6PDH	0.2 U
Glutamate Dehydrogenase	0.05 U
Hexokinase	0.1 U
Lactate Dehydrogenase	0.3 U
L-Alanine	0.3 mg
NAD	0.04 mg
NADH	0.06 mg
Peroxidase	0.1 U
Sarcosine Oxidase	0.4 U
TBHBA	0.2 mg
Urease	0.03 U

Composition

lpha -Ketoglutaric Acid Sodium Salt

Quantity/Panel 0.25 mg

Reagent Storage:

- The reagent disc should be stored at $2 \sim 8^{\circ}$ C.
- The expiry date of the reagent is printed on the outside of the sealed pouch of reagent disc. Do not use if the reagent disc has expired.

4. Specimen Collection and Preparation

Specimen Collection:

- Specimens suitable for skyla Preanesthetic Panel include lithium heparinized whole blood, lithium heparinized plasma, serum and quality control materials. The sample requirement is 200 µL. (±10 µL tolerance are allowable)
- If applicable, local regulatory or standard operating procedures of your organization should be followed for the collection, preservation and handling of specimens.

Note: Do not use specimens containing other coagulants. That would cause an incorrect test results.

Specimen Preparation:

Before applying a sample to the reagent disc, gently rotate the sample tube up and down several times, to confirm the sample is homogeneous (evenly mixed). If the sample is whole blood, do not shake the sample container vigorously to avoid occurrence of hemolysis.

Note:

- 1. Perform testing within 10 minutes after applying the sample to the reagent disc.
- 2. The use of whole blood specimens with hematocrits (Hct) higher than 60% may affect the test results.

Note: For further information in specimen collection and preparation, please refer to "skyla Analyzer Operator's Manual"

5. Test Procedures

Material Preparation:

1 piece of the reagent disc of skyla Preanesthetic Panel

Required materials not included in the panel:

skyla Analyzer

Sample collection container

Micropipette / Tips

Test Conditions:

Test should be carried out in an environment with temperatures of 10°C~32°C. Each test will take about 15 minutes. During the test, chamber in the analyzer keeps the temperature at 37°C for stable assay.

Test Steps:

- 1. Open the aluminum pouch and remove the reagent disc.
- 2. Remove the diluent container sealing.
- 3. Using a micropipette to inject 200 μ L of the sample into the reagent disc through the sample port.
- 4. Press the "start" button on the screen to initiate testing.
- 5. Place the reagent disc to the analyzer drawer, and press the "ok" button on the screen to analysis.

For details on the operating steps and instrument setting, please refer to "skyla Analyzer Operator's Manual".

Note:

- 1. To operate the reagent disc or instrument, please wear lab gloves and other protective gear to avoid contamination by specimen.
- 2. The used reagent disc and tips should be discarded as biomedical waste, and treat according to the local legal requirements.
- 3. Testing should be performed within 20 minutes after the pouch is opened.
- 4. Do not place the reagent disc at the environment more than 25°C and longer than 48 hours prior to use.
- 5. If the reagent disc or its package is damaged or is over the expiry date, do not use it.

6. Calibration

The barcode on every manufactured reagent disc contains all information required for calibration of the test items. The analyzer will automatically read the barcode information during testing.

7. Quality Control

- Please refer to the instruction manual for the preparation and use of quality control materials. For discrepancy results, the confirmatory test was suggested to carry out with the automated laboratory analyzer, or to contact with our technical support.
- External quality control materials can be used for the accuracy monitor of skyla system. The recommended frequency of QC testing is as follows, otherwise please follow local legal requirements or the standard operating procedures of your organization
 - At least every 30 days.
 - Before a new batch of reagents is used for testing.
 - When the analyzer was moved or the operating environment significantly changed.

8. Reference interval

The table below shows the reference interval for each test item. It is recommended that every laboratory or test site should establish its own reference interval from its patient population.

	Test Item	Referer	nce Interval	Reference (SI U1	
ALB	Canine	2.6 - 4.6	g/dL	26 - 46	g/L
ALD	Feline	2.5 - 4.6	g/dL	25 - 46	g/L
ALP	Canine	0 - 212	U/L	0 - 212	U/L
ALP	Feline	0 - 111	U/L	0 - 111	U/L
A I T	Canine	0 - 88	U/L	0 - 88	U/L
ALT	Feline	0 - 116	U/L	0 - 116	U/L
BUN	Canine	6.0 - 26.0	mg/dL	2.1 - 9.3	mmol urea/L
	Feline	13.0 - 37.0	mg/dL	4.6 - 13.2	mmol urea/L
CDEA	Canine	0.4 - 1.6	mg/dL	35-141	μmol/L
CREA	Feline	0.7 - 2.0	mg/dL	62-177	μmol/L
CLU	Canine	60 - 110	mg/dL	3.3 - 6.1	mmol/L
GLU	Feline	53 - 150	mg/dL	2.9 - 8.3	mmol/L
TP	Canine	5.2 - 8.2	g/dL	52 - 82	g/L
	Feline	5.7 - 8.9	g/dL	57 - 89	g/L

9. Limitation

Physiological interferences in blood include hemolysis, icterus, and lipemia. For every test item,

2 Levels serum pool supplemented with known concentrations of the endogenous substances were used for the testing. Significant interference is defined as a >20% shift in the test result. (Note: Highest tested concentration for Hemoglobin: 600 mg/dL; Bilirubin (unconjugated): 62.5 mg/dL, Bilirubin (conjugated): 57.5 mg/dL; Intralipid: 0.55%)

	Substar	nce concentration with int	erferences of less than 2	20%
Test Item	Hemoglobin	Bilirubin (unconjugated)	Bilirubin (conjugated)	Intralipid
ALB	300 mg/dL	62.5 mg/dL	57.5 mg/dL	0.2%
ALP	600 mg/dL	25.9 mg/dL	57.5 mg/dL	0.1%
ALT	500 mg/dL	34.5 mg/dL	28.4 mg/dL	0.1%
BUN	500 mg/dL	42.1 mg/dL	29.3 mg/dL	0.43%
CREA	200 mg/dL	25.9 mg/dL		0.17%
GLU	600 mg/dL	62.5 mg/dL	57.5 mg/dL	0.3%
TP	300 mg/dL	62.5 mg/dL	57.5 mg/dL	0.2%

10. Performance Characteristics

Dynamic range:

The dynamic range for each test item showed as below.

Test Item	Dynamic Rang	ge	Dynamic Rang	ge (SI Unit)
ALB	1.0 - 6.0	g/dL	10 - 60	g/L
ALP	41 - 2000	U/L	41 - 2000	U/L
ALT	20 - 1100	U/L	20 - 1100	U/L
BUN	2.0 - 140	mg/dL	0.7 - 50.0	mmol urea/L
CREA	0.3 - 20.0	mg/dL	27 - 1768	µmol/L
GLU	30 - 550	mg/dL	1.7 - 30.5	mmol/L
TP	1.5 - 10.0	g/dL	15 - 100	g/L

Method Comparison:

The SIMENS ADVIA 1800 was used as comparative method in the study. The tests are performed by using the same clinical serum sample for two methods.

Marke	er	R ²	Slope	Intercept	Sample No.	Sample Range
ALB	Canine	0.9848	0.9999	0.0000	38	2.7-5.9 g/dL
ALD	Feline	0.9676	1.0000	0.0000	38	3.1-6.4 g/dL
ALP	Canine	0.9626	0.9999	-0.0059	32	53-1246 U/L
ALP	Feline	0.9581	0.9998	-0.0010	32	24-263 U/L
A I T	Canine	0.9872	0.9934	-2.4272	32	28-284 U/L
ALT	Feline	0.9951	1.0290	0.2758	32	31-243 U/L
DUN	Canine	0.9967	0.9843	0.6679	41	9.7-128.4 mg/dL
BUN	Feline	0.9923	1.0067	-0.7677	40	17.5-126.9 mg/dL
CREA	Canine	0.9968	1.0526	-0.0305	38	0.47-16.93 mg/dL

Marke	er	R ²	Slope	Intercept	Sample No.	Sample Range
	Feline	0.9928	1.0498	-0.2650	38	1.2-17.65 mg/dL
GLU	Canine	0.9953	1.0001	0.0089	43	78-558 mg/dL
GLU	Feline	0.9957	0.9956	2.1761	44	93-549 mg/dL
TD	Canine	0.9603	0.9999	0.0000	38	5.2-9.5 g/dL
TP	Feline	0.9883	0.9999	0.0000	38	6.3-10.3 g/dL

	Symbol Index					
REF	Catalogue number	Ĩ	Consult instruction for use			
LOT	Batch code	\sum	Use by			
	Manufacturer	Ce	CE mark			
	Temperature limitation		Caution			
\otimes	Do not reuse	Σ	Sufficient for			

Supplier	: SKYLA CORPORATION HSINCHU SCIENCE PARK BRANCH
Address	: 1F, No.8, Dusing Rd., Hsinchu Science Park, East Dist., Hsinchu City, Taiwan
Customer service/ Technical support	: +886-3-611-8511
Website	: www.skyla.com

Issue Date: 2012/03/19 Revised Date: 2020/08/21 PN:7B25000032HH